Business Context and Reporting Period
Bone Biologics Corp, an emerging growth company, filed this Form 8-K on April 9, 2019, reporting the entry into a Material Definitive Agreement. The company focuses on the development and commercialization of Nell-1, a recombinant human protein growth factor essential for normal bone development.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data provided is limited to specific contractual obligations and payments associated with the new agreement:
- Reimbursement of Past Expenses: Approximately $96,653 for past patent expenses.
- Development Milestones: Four new milestones totaling $2,850,000 contingent on the development of a PEGylated Licensed Product.
- Royalty Obligation: 3% royalty on Net Sales for products covered by Newly Added Patent Rights.
- Sublicense Income Sharing: 30% sharing of Sublicense Income attributable to Newly Added Patent Rights.
Material Changes Versus Prior Period
The filing details amendments to the 2017 Exclusive License Agreement with The Regents of the University of California. Principal changes include:
- Addition of several new patent families directed to the Licensed Product.
- Introduction of a formal dispute resolution mechanism regarding value allocation for combination products and sublicensing income.
- New development obligations for a PEGylated Licensed Product, with a target First Commercial Sale by the end of 2031.
- Implementation of new financial terms including the milestones, royalties, and expense reimbursements listed above.
Guidance, Outlook, and Risks
Outlook: The company has committed to a development timeline concluding with a First Commercial Sale of the PEGylated Licensed Product by the end of 2031.
Risks and Contingencies: The agreement introduces a dispute resolution process where the Regents can challenge the Company's allocation of value. If unresolved after a 30-day conference, the matter is referred to a neutral expert. The company also assumes ongoing patent expenses for the newly added rights.
Investor Verification Checklist
- Verify the specific scope of the "Newly Added Patent Rights" and their impact on the company's intellectual property portfolio.
- Confirm the company's current cash position to ensure it can meet the immediate $96,653 reimbursement and future milestone payments.
- Review the full text of the Amended and Restated Exclusive License Agreement (Exhibit 10.1) for detailed terms on the dispute resolution mechanism.
- Assess the feasibility of the 2031 commercialization target for the PEGylated product given the company's current development stage.